ATE452204T1 - Screening-methoden unter verwendung eines strukturmodells von fih - Google Patents

Screening-methoden unter verwendung eines strukturmodells von fih

Info

Publication number
ATE452204T1
ATE452204T1 AT03758318T AT03758318T ATE452204T1 AT E452204 T1 ATE452204 T1 AT E452204T1 AT 03758318 T AT03758318 T AT 03758318T AT 03758318 T AT03758318 T AT 03758318T AT E452204 T1 ATE452204 T1 AT E452204T1
Authority
AT
Austria
Prior art keywords
fih
structural model
structural
screening methods
chemical entity
Prior art date
Application number
AT03758318T
Other languages
English (en)
Inventor
Peter John Ratcliffe
Christopher William Pugh
Christopher Joseph Schofield
Kirsty Sarah Hewitson
Jonathan Mark Elkins
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224102A external-priority patent/GB0224102D0/en
Priority claimed from GB0226598A external-priority patent/GB0226598D0/en
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE452204T1 publication Critical patent/ATE452204T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Epidemiology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Computing Systems (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03758318T 2002-10-16 2003-10-16 Screening-methoden unter verwendung eines strukturmodells von fih ATE452204T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0224102A GB0224102D0 (en) 2002-10-16 2002-10-16 Inhibitors
GB0226598A GB0226598D0 (en) 2002-11-14 2002-11-14 Chemical inhibitors
PCT/GB2003/004492 WO2004035812A2 (en) 2002-10-16 2003-10-16 Asparaginyl hydroxylases and modulators thereof

Publications (1)

Publication Number Publication Date
ATE452204T1 true ATE452204T1 (de) 2010-01-15

Family

ID=32109245

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03758318T ATE452204T1 (de) 2002-10-16 2003-10-16 Screening-methoden unter verwendung eines strukturmodells von fih

Country Status (11)

Country Link
US (1) US7778779B2 (de)
EP (2) EP1554394B1 (de)
JP (1) JP4465276B2 (de)
AT (1) ATE452204T1 (de)
AU (1) AU2003274330B2 (de)
CA (1) CA2502541A1 (de)
DE (1) DE60330587D1 (de)
ES (1) ES2337043T3 (de)
MX (1) MXPA05004033A (de)
PL (1) PL376770A1 (de)
WO (1) WO2004035812A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530522A (ja) 2004-03-26 2007-11-01 アイシス・イノベーション・リミテッド アッセイ
BRPI0513359A (pt) 2004-07-15 2008-05-06 Amr Technology Inc tetraidroisoquinolinas substituìdas por arila e heteroarila e uso destes para bloquear a recaptação de norepinefrina, dopamina, e serotonina
GB0519605D0 (en) 2005-09-26 2005-11-02 Isis Innovation Assay
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
EP2327696A1 (de) 2006-06-26 2011-06-01 Warner Chilcott Company, LLC Prolylhydroxylase-Hemmer und Verfahren zu ihrer Anwendung
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010069600A2 (en) 2008-12-19 2010-06-24 European Molecular Biology Laboratory (Embl) Polypeptide fragments comprising endonuclease activity and their use
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
CN102638982B (zh) * 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
EP2429296B1 (de) * 2009-05-12 2017-12-27 Albany Molecular Research, Inc. 7-([1,2,4,]triazol[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorphenyl)-1,2,3,4- tetrahydroisochinolin und seine verwendung
WO2011057121A1 (en) 2009-11-06 2011-05-12 Akebia Therapeutics Inc. Compositions and methods for treating colitis
KR101637246B1 (ko) 2009-12-04 2016-07-07 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
NO2686520T3 (de) 2011-06-06 2018-03-17
KR101652606B1 (ko) 2011-06-06 2016-08-30 아케비아 테라퓨틱스 인코포레이티드 암 치료 방법으로서 저산소증 유도 인자-2 알파를 안정화시키기 위한 화합물 및 조성물
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
US9771356B2 (en) * 2012-09-21 2017-09-26 Rhode Island Hospital Inhibitors of beta-hydroxylase for treatment of cancer
SG11201509998WA (en) 2013-06-13 2016-01-28 Akebia Therapeutics Inc Compositions and methods for treating anemia
CN107427503A (zh) 2015-01-23 2017-12-01 阿克比治疗有限公司 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
TWI836883B (zh) 2015-04-01 2024-03-21 美商阿克比治療有限公司 用於治療貧血之組合物及方法
US10312653B2 (en) 2015-05-06 2019-06-04 Milwaukee Electric Tool Corporation Hydraulic tool
CN116283877A (zh) 2016-07-29 2023-06-23 赛诺维信制药公司 化合物、组合物及其用途
SG11201900687VA (en) 2016-07-29 2019-02-27 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
WO2018151861A1 (en) 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
EP3752508A1 (de) 2018-02-16 2020-12-23 Sunovion Pharmaceuticals Inc. Salze, kristallformen und herstellungsverfahren dafür
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
EP4135690B1 (de) 2020-04-14 2026-03-25 Sumitomo Pharma America, Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamin zur behandlung, vorbeugung und/oder bewältigung einer neurologischen und/oder psychiatrischen störung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001251467A1 (en) 2000-05-17 2001-12-03 Princeton University Methods of making models, methods of using models of murg, compounds that bind, inhibit or stimulate muret proteins, and therapeutic compositions thereof
GB0017323D0 (en) 2000-07-15 2000-08-30 Univ St Andrews Enzyme
US7630838B2 (en) 2000-09-22 2009-12-08 American Home Products Corporation Method for identifying agents that interact with beta-site APP cleaving enzyme (BACE)
AU2002241154A1 (en) 2001-03-21 2002-10-03 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
AUPR773801A0 (en) 2001-09-18 2001-10-11 Adelaide Research & Innovation Pty Ltd Asparagine hydroxylation of the cad domain of a hif protein

Also Published As

Publication number Publication date
WO2004035812A2 (en) 2004-04-29
MXPA05004033A (es) 2005-06-08
CA2502541A1 (en) 2004-04-29
US7778779B2 (en) 2010-08-17
AU2003274330A1 (en) 2004-05-04
DE60330587D1 (de) 2010-01-28
EP2156830A1 (de) 2010-02-24
US20070048728A1 (en) 2007-03-01
WO2004035812A3 (en) 2004-08-19
JP2006504415A (ja) 2006-02-09
JP4465276B2 (ja) 2010-05-19
AU2003274330B2 (en) 2009-06-04
EP1554394A2 (de) 2005-07-20
EP1554394B1 (de) 2009-12-16
ES2337043T3 (es) 2010-04-20
PL376770A1 (pl) 2006-01-09

Similar Documents

Publication Publication Date Title
ATE452204T1 (de) Screening-methoden unter verwendung eines strukturmodells von fih
Wisshak et al. Ocean acidification accelerates reef bioerosion
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
DK0944731T3 (da) Enzymsensor
DE602005027646D1 (de) Verfahren zum Betrieb eines Navigationssystems zum Melden aktualisierter Teile einer geographischen Datenbank
ATE496141T1 (de) Verfahren und system zum analysieren von reaktionen unter verwendung eines informationssystems
DE60334365D1 (de) Leistungsverbesserung einer analytenüberwachungsvorrichtung
EA200501193A1 (ru) Улучшенный способ и система для выявления и/или прогнозирования биологических аномалий, например церебральных нарушений
ATE462710T1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
Wang et al. Responses of soil organic and inorganic carbon vary at different soil depths after long‐term agricultural cultivation in Northwest China
ATE507512T1 (de) Verfahren, computerprogramm mit programmcode- mitteln und computerprogramm-produkt zur analyse von einflussgrössen auf einen brennvorgang in einer brennkammer unter verwendung eines trainierbaren, statistischen modells
CN116825220B (zh) 基于连续性分布函数的海洋有机碳降解过程评估方法
DE69928250D1 (de) Analytisches verfahren unter verwendung von multipelviren-markierung
ATE221657T1 (de) Entstörung durch rheumafaktoren
DE602006017058D1 (de) Verfahren zur stratifizierung von herzinsuffizienz
Lu et al. Multivariate calibration models based on the direct analysis of near-infrared single-beam spectra
DE3850346D1 (de) Verfahren zur Selbstdurchführung von Enzymkinetik.
ATE459077T1 (de) Verfahren und vorrichtung zur bestimmung der aufzeichnungsparameter von optischen platten
ATE527596T1 (de) Erhalten von konfigurationsdaten für ein datenverarbeitungsgerät
DE602005015627D1 (de) Verfahren zur messung von proinsulin und c-peptid sowie kit dafür
Boushaba et al. Dynamics of the ‘echo’effect in a phytoplankton system with nitrogen fixation
Roberto et al. Changes in biological properties and antioxidant capacity of an agricultural soil amended with sewage sludge
DE602006007734D1 (de) Verfahren und system zur echtzeitanalyse von biosensordaten
ATE355527T1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
WO2002072551A3 (en) A non-traumatic model for neurogenic pain

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties